Navigation Links
Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
Date:12/8/2008

Lead Oral Candidate Demonstrates Proteasome Inhibition and Anti-Tumor Activity

SOUTH SAN FRANCISCO, Calif., Dec. 8 /PRNewswire/ -- Proteolix, Inc., today announced results from a series of in vitro and in vivo studies designed to characterize PR-047, the company's oral proteasome inhibitor. These data were presented today in a poster titled "Preclinical Pharmacology and In Vitro Characterization of PR-047, An Oral Inhibitor of the 20S Proteasome" (Abstract # 3671) at the 50th Annual Meeting of the American Society of Hematology (ASH). PR-047 is the first oral compound in a new class of highly specific proteasome inhibitors. Carfilzomib, the lead compound in this class, will be the subject of two oral presentations of Phase 2 data on Tuesday, December 9th. PR-047 was designed by Proteolix scientists to combine the pharmacological properties of carfilzomib with the convenience of oral dosing.

Researchers evaluated PR-047's mechanism, bioavailability and activity in a series of preclinicalstudies. Like carfilzomib, PR-047 was shown to target the chymotrypsin-like activity of the proteasome and induce tumor cell death across multiple human cell lines. Oral administration of PR-047 in rodents and monkeys resulted in rapid and prolonged dose-dependent inhibition of the proteasome. Furthermore, significant proteasome inhibition was achieved at doses well below the maximum-tolerated dose even when administered over five consecutive days, suggesting that repeated daily dosing may be feasible with this molecule. Administration of PR-047 resulted in consistent anti-tumor responses in hematological and solid tumor xenograft models at doses below the maximum-tolerated dose.

"We are pleased by the preclinical data achieved to date with PR-047, which demonstrates a promising combination of proteasome inhibition, anti-tumor activity, bioavailability and tolerability," said Mark
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Proteolix Raises $79 Million in Series C Financing
2. Proteolixs Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Frost & Sullivan Presents CorMatrix Cardiovascular Inc. with 2008 Healthcare Innovation Award for the Treatment of Cardiovascular Disease
5. AmeriCares Presents Power of Partnership Award to Baxter
6. Prominent Urologist Dr. David B. Samadi Presents Breakthrough Robotic Surgery Techniques on OR Live Webcast
7. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
8. Northern Antibiotics Presents New Data on Novel Polymyxin Compounds at the Joint ICAAC/IDSA 2008
9. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
10. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
11. GeoVax Presents Data at AIDS Vaccine 2008 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014 Cardioxyl Pharmaceuticals, Inc. ... been shown to be effective in animal models following ... to intravenous infusions that could pave the way for ... presented yesterday at the Heart Failure Society of America,s ... Las Vegas . The research, ...
(Date:9/16/2014)... TN (PRWEB) September 16, 2014 ... new initiatives to position themselves for their ... for labeling and encoding, Pharma Packaging Solutions ... new hardware and software and new procedures. ... current Good Manufacturing Practices (cGMP), Pharma Packaging ...
(Date:9/16/2014)... ORLEANS , Sept. 16, 2014 In ... Austin, Texas -based cybersecurity company focused on authentication ... ONE, will support the ability to generate a OTP ... As a pioneer of user-based RFID authentication, 2FA,s ... for physical access, for many years. RFID authentication is ...
(Date:9/15/2014)... 2014   Global Science & Technology, Inc. ... and services for satellite and weather systems, was ... Services (OASIS) from the General Services Administration (GSA) ... provide the government best-value solutions for complex professional ... in Pool 4. The OASIS SB award has ...
Breaking Biology Technology:Cardioxyl Presents Oral Heart Failure Treatment Data For Its Experimental HNO Prodrug At HFSA 18th Annual Scientific Meeting 2Adding Serialization Capabilities and Expanded Capacity, Pharma Packaging Solutions Is Preparing for 89th Year of Business 22FA, Inc. Announces RFID-based One-Time Password (OTP) Authentication 2Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 2Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 3
... Approval Shortly -- , , LAKE FOREST, Ill., June ... world leader in generic injectable pharmaceuticals, today announced that the ... granted summary judgment of non-infringement in Hospira,s favor with regard ... tentative approval from the U.S. Food and Drug Administration (FDA) ...
... LANSING, Mich., June 18 Fortune Magazine has named ... its annual list of the "40 best stocks to retire on." ... list in 2002, stating: "We wanted to assemble a diversified, dependable ... could soar when the market did but also hold steady during ...
... Optical Industry Ltd. (Nasdaq: SHMR ) a leading ... market, announced today that its annual report on Form 20-F, ... 31, 2008, as filed with the Securities and Exchange Commission ... www.shamir.co.il ). Shareholders may receive a hard copy of the ...
Cached Biology Technology:Hospira Receives Favorable Court Decision on Eloxatin(R) 2Hospira Receives Favorable Court Decision on Eloxatin(R) 3Neogen Named to Fortune's List of 40 Stocks 'To Retire On' 2Shamir Optical Industry Ltd. Announces Availability of Its Annual Report on Form 20-F Through Its Website 2
(Date:9/15/2014)... containing carbon-halogen bonds are produced naturally across all kingdoms ... products with a broad range of biological activities. The ... a profound influence on their molecular properties. ... has been to find the late-stage, site-specific incorporation of ... replacing an sp C-H bond (one of the most ...
(Date:9/15/2014)... released today by the National Academy of Sciences, ... and strategies for the program and will guide ... years (2015-2020). In addition, the program announced ... in 2015, will include exploratory grants, early-career research ... $500 million, 30-year program to be run by ...
(Date:9/15/2014)... cognitive function may play roles in one,s musical aptitude, ... timbre, tone durations, and formal structure in music. , ... that extremes in musical aptitude (extreme capacity/no capacity) are ... having moderate aptitude. , "This is a typical feature ... and it is influenced to varying degrees by environmental ...
Breaking Biology News(10 mins):Pitt chemical biologist finds new halogenation enzyme 2NAS Gulf Research Program announces strategic vision, initial opportunities 2NAS Gulf Research Program announces strategic vision, initial opportunities 3NAS Gulf Research Program announces strategic vision, initial opportunities 4
... have discovered a gene in plants that disrupts fertilization ... both the female and male reproductive cells. Their ... in the journal Current Biology, has been named the ... properties. Mutations that do not allow fertilization are ...
... of Grenoble, in France, have discovered that ... by doxorubicin and trastuzumab exposures. The research ... protects against acute chemotherapy toxicity in isolated ... January 2008 issue of Experimental Biology and ...
... - A group of signaling proteins known as Wnt ... muscle and other tissues - depend on a complex ... tissue-building cell sites, according to a study at Cincinnati ... the Retromer Complex - breaks down, the delivery of ...
Cached Biology News:Biologists find unusual plant gene: abstinence by mutual consent 2Biologists find unusual plant gene: abstinence by mutual consent 3A search for protection against chemotherapy cardiotoxicity 2Certain diseases, birth defects may be linked to failure of protein recycling system 2
Agarase cleaves agarose to neoagaro-oligosaccharides, and is used for,quantitative, gentle recovery of DNA from low melting point agarose....
Form: Ready to use Applications: ELISA...
Form: Concentrated Applications: ELISA...
Form: Ready to use Applications: Western Blot, ELISA...
Biology Products: